Mobidiag Granted Patents Covering The Method And Related Kit For Detecting Antibiotic Resistant Bacteria

ESPOO, Finland--(BUSINESS WIRE)--Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the issuance of two new patents complementing the Australian Patent n°2010247321 obtained in June 2016: US Patent n°9593381 and Japanese Patent n°6054178 covering a method and a kit for detecting antibiotic resistant bacteria, and more specifically, screening for carbapenemase genes causing carbapenem resistance in bacteria.

“At Mobidiag, we have been developing fast and reliable tests for the detection of infectious diseases, including antibiotic resistance with our Amplidiag® Carba+VRE kit and wider panels soon to come. These new additions to Mobidiag’s intellectual property are key in our global strategy and definitely strengthen our commitment towards the fight against antibiotic resistance, a major worldwide health concern nowadays” said Tuomas Tenkanen, CEO at Mobidiag.

With an estimated 10 million deaths a year by 2050¹, antimicrobial resistance is currently one of the biggest threats to global health. Mistreatment and excessive use of antibiotics have given rise to multidrug resistant organisms, also called superbugs, making antibiotics less and less effective. New diagnostic tools are then needed to support early decision making prior to any treatment delivery. Reliable and fast diagnostics would 1- ensure patient care and safety by detecting infection type allowing selection of the appropriate treatment with or without antibiotics and 2- detecting rapidly superbacteria to isolate infected patients, treat them accordingly and avoid infection spreading.

¹ Jim O’Neill et al. (May 2016). Tackling drug-resistant infections globally: Final report and Recommendations, The Review on Antimicrobial Resistance, p.11

About Amplidiag® CarbaR+VRE (CE-IVD)
Amplidiag® CarbaR+VRE is a molecular test allowing detection of 9 groups of the most important carbapenemase-producing organisms. These bacteria may cause multiple antibiotics to perform inefficiently, which in turn can lead to serious infections, particularly in healthcare settings. This multiplex PCR test gives results within a few hours directly from pure culture samples as opposed to days with current culture-based screening methods.

About Mobidiag Ltd.
Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.
Mobidiag addresses both high to medium volume screening with the new Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results, and the upcoming Novodiag® platform & associated panels for a fully automated solution and suitable for smaller volumes and labs. Visit www.mobidiag.com.